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Abstract
Background: Increased concentrations of choline-containing compounds are frequently observed in breast
carcinomas, and may serve as biomarkers for both diagnostic and treatment monitoring purposes. However,
underlying mechanisms for the abnormal choline metabolism are poorly understood.
Methods: The concentrations of choline-derived metabolites were determined in xenografted primary human
breast carcinomas, representing basal-like and luminal-like subtypes. Quantification of metabolites in fresh frozen
tissue was performed using high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS
MRS).
The expression of genes involved in phosphatidylcholine (PtdCho) metabolism was retrieved from whole genome
expression microarray analyses.
The metabolite profiles from xenografts were compared with profiles from human breast cancer, sampled from
patients with estrogen/progesterone receptor positive (ER+/PgR+) or triple negative (ER-/PgR-/HER2-) breast cancer.
Results: In basal-like xenografts, glycerophosphocholine (GPC) concentrations were higher than phosphocholine
(PCho) concentrations, whereas this pattern was reversed in luminal-like xenografts. These differences may be
explained by lower choline kinase (CHKA, CHKB) expression as well as higher PtdCho degradation mediated by
higher expression of phospholipase A2 group 4A (PLA2G4A) and phospholipase B1 (PLB1) in the basal-like model.
The glycine concentration was higher in the basal-like model. Although glycine could be derived from energy
metabolism pathways, the gene expression data suggested a metabolic shift from PtdCho synthesis to glycine
formation in basal-like xenografts. In agreement with results from the xenograft models, tissue samples from triple
negative breast carcinomas had higher GPC/PCho ratio than samples from ER+/PgR+ carcinomas, suggesting that
the choline metabolism in the experimental models is representative for luminal-like and basal-like human breast
cancer.
Conclusions: The differences in choline metabolite concentrations corresponded well with differences in gene
expression, demonstrating distinct metabolic profiles in the xenograft models representing basal-like and luminal-
like breast cancer. The same characteristics of choline metabolite profiles were also observed in patient material
from ER+/PgR+ and triple-negative breast cancer, suggesting that the xenografts are relevant model systems for
studies of choline metabolism in luminal-like and basal-like breast cancer.
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Background
Optimal treatment of individual breast cancer patients is
still a major challenge in oncology. An approach to
improve and individualize the treatment beyond the
markers and stratification tools used at present, is
through molecular subtyping of breast cancer [1]. Based
on variation in gene expression profiles, five molecular
subtypes have been identified [1-3]. The gene expression
patterns of these subtypes are similar across multiple
samples from the same tumor, shows no treatment-
related changes and have been reproduced in a number
of patient populations [2-7]. However, the current use
of these molecular subgroups in clinical practice
remains limited. Further understanding of the differ-
ences in biology between the various subtypes is needed
in order to predict therapeutic response and provide
individual treatment strategies based on gene expression
profiles [8].
Elevated levels of choline metabolites is a known fea-
ture of breast cancer, and it has been shown that drugs
targeting choline metabolism have selective in vivo and
in vitro cytotoxic efficacy against a variety of cancer
types [9-13]. Magnetic resonance spectroscopy (MRS) is
a valuable tool for studies of choline metabolism both in
patients and in experimental systems [14]. High resolu-
tion magic angle spinning (HR MAS) MRS of ex vivo
tissue samples has been particularly useful, as it allows
assessment of individual choline metabolites in intact
tissue specimens. Increased concentrations of choline,
phosphocholine (PCho) and glycerophosphocholine
(GPC) has been demonstrated both in cultured breast
cancer cells [15-17] and in human breast cancer biopsies
[18-21]. It has also been shown that choline metabolism
is altered following chemotherapy, suggesting the possi-
bility of using MRS for therapy monitoring [22-24].
However, to utilize these findings in diagnosis and indi-
vidualized therapy monitoring of breast cancer patients,
a better understanding of the choline metabolism
abnormalities on a molecular level is needed.
Several studies investigating expression of genes
involved in metabolism of phosphatidylcholine (PtdCho)
have been performed using breast cancer cell lines
[16,17,25,26]. PtdCho is an important cellular membrane
lipid, and this metabolic pathway directly involves cho-
line, PCho and GPC. In addition, genes involved in
transmembrane choline transport and conversion of
choline to glycine have been suggested to be important
for the observed choline concentrations in breast cancer
cells [16,27]. The choline metabolism profiles observed
in cultured breast cancer cells are more homogenous
than those seen in human biopsies. In order to bridge
the gap between in vitro research and clinical breast
cancer, there is a great need for animal models
representing different types of breast cancer for use in
functional and mechanistic studies. Serial orthotopic
transplantation of clinical tumor isolates in immunodefi-
cient mice is considered a promising tool for investiga-
tion of human breast cancer biology [28]. Establishment
of relevant experimental models of basal-like breast can-
cer is especially important both in order to understand
the special characteristics of this subtype, to find poten-
tial new molecular targets for therapy and to establish
potential biomarkers for monitoring response to
therapy.
The aim of this study was to compare the choline
metabolite patterns in animal models of basal-like and
luminal-like subtypes of breast cancer, and to study the
expression of genes related to choline metabolism in
order to explain the differences between the two breast
cancer subtypes. The two orthotopic xenograft models
used, MAS98.12 and MAS98.06, represent basal-like and
luminal-like subtypes of breast cancer, respectively [29].
Both models have been established by direct inoculation
of primary human tumor material into immunodeficient
animals. The content of creatine, choline, PCho, GPC,
taurine and glycine in the xenografts as well as human
breast cancer tissue samples was determined using HR
MAS MRS. The molecular basis of the observed differ-
ences in choline metabolism was studied using gene
expression microarray data. In order to evaluate if the
xenograft models are representative for human disease,
the metabolic profiles were compared to corresponding
profiles from patients with ER+/PgR+ or triple negative
breast cancer.
Methods
Animal model
The MAS98.12 and MAS98.06 tumor models were
established by orthotopic implantation of biopsy tissues
from primary mammary carcinomas in SCID mice as
previously described [29]. Both the primary carcinomas
and the xenograft models have been characterized using
gene expression profiling. These analyses demonstrated
that the primary carcinomas could be classified as lumi-
nal-like and basal-like subtypes of breast cancer, and
that these molecular subtypes were retained in the
MAS98.06 (luminal-like) and MAS98.12 (basal-like)
xenografts. Relevant characteristics of the models are
presented in Table 1. The tumors are serially trans-
planted. Tissue used for HR MAS MRS was from pas-
sage 47 (MAS98.12) and 28 (MAS98.06), and tissue
used for RNA microarray analysis was from passage 45
(MAS98.12) and 25 (MAS98.06).
The animals were kept under pathogen-free condi-
tions. Housing conditions included temperature between
19°C and 22°C, humidity between 50% and 60%, 20 air
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changes/hr and a 12 hr light/dark cycle. The animals
were fed RM1 diet (Scanbur BK, Norway) and distilled
tap water ad libitum. The drinking water was supple-
mented with 17-b-estradiol at a concentration of 4 μg/
ml in order to ensure stimulation of the estrogen recep-
tors and promote tumor growth in the MAS98.06 xeno-
grafts. With respect to tumor growth rate, this estrogen
supplement correspond to the use of s.c. continuous
release 17-b-estradiol pellets (1.7 mg/pellet), which were
used during establishment of the animal models [29].
To provide equal experimental conditions, the
MAS98.12 xenografts also received estradiol supplement.
This could in theory cause non-ER-mediated effects on
choline metabolite profile. However, the similarities
between human tissue samples and xenograft tissue sug-
gest that such effects are insignificant in ER-breast
cancer.
Following sacrifice by cervical dislocation, tumor tis-
sue was harvested from 10 animals from each model for
the HR MAS MRS analyses and for 6 animals from each
model for gene expression microarray analyses, at tumor
diameters of approximately 13-15 mm. Samples were
put in cryogenic vials and immersed in liquid nitrogen
immediately after dissection and stored under cryogenic
conditions until analysis. All procedures and experi-
ments involving animals were approved by The National
Animal Research Authority, and carried out according
to the European Convention for the Protection of Verte-
brates used for Scientific Purposes.
Human tissue samples
For comparison of xenograft models with human breast
cancer tissue, biopsies from 22 breast cancer patients
were identified in our internal database based on histo-
pathology/immunohistochemistry data. Patients with
either ER+/PgR+ (n = 14) or triple negative (n = 8)
phenotype were included. Biopsy material was obtained
during surgery and immediately frozen in liquid nitro-
gen. Histopathology and immunohistochemistry data for
the selected patients was obtained from hospital records.
Patient and tumor characteristics are presented in Table
2. The biopsy material was subject to HR MAS MRS
analysis and subsequent histopathological evaluation
using hematoxylin/eosin (HE) staining. The use of
patient material was approved by the Regional Commit-
tee for Medical and Health Research Ethics, and
informed written consent was obtained from all
included patients.
HR MAS MRS of xenograft tissue
Storage time before HR MAS MRS analysis was less
than one month for all 20 samples. Macroscopically
viable tumor tissue was cut to fit a 30 μl disposable
insert (Bruker Biospin Corp.), prefilled with 3 μl PBS
made on D2O containing 98.8 mM trimethylsilyltetra-
deuteropropionic acid (TSP) for chemical shift referen-
cing. The average sample weight was 15 ± 3 mg (mean
± SD). HR MAS MR spectra were recorded using a Bru-
ker AVANCE DRX600 spectrometer equipped with a
1H/13C HR MAS probe (Bruker BioSpin Corp.). Samples
were spun at 5 kHz with an instrumental temperature
setting of 4°C. A pulse-acquired experiment including
the ERETIC sequence (ereticpr.drx; Bruker) was per-
formed for all samples. The ERETIC signal was posi-
tioned at -1.0 ppm. The water resonance was saturated
for 15 seconds (60 dB continuous wave), followed by a
60-degree pulse for excitation. Signals were collected
over a sweep width of 16.7 ppm. 128 FIDs were
acquired into 64K points during 3.28 seconds. Spectra
were Fourier transformed into 128K after 0.3 Hz expo-
nential line broadening and chemical shifts were cali-
brated to the TSP singlet at 0 ppm. Spectral
Table 1 Summary of xenograft characteristics
Basal-like xenograft (MAS98.12) Luminal-like xenograft (MAS98.06)
Primary tumor Xenograft Primary tumor Xenograft
Tumor grade Grade III IDC NA Grade III IDC NA
Lymph node status No metastasis NA Metastasis to 12 of 25 nodes NA
No distant metastases
Differentiation Poorly differentiated Poorly differentiated Well differentiated Poorly differentiated
Hormone receptor status ER-/PgR+** ER-/PgR- ER+/PgR+ ER+/PgR+
ERBB2 amplification* Negative Negative Negative Negative
Intrinsic molecular subtype Basal-like Basal-like Luminal-like Luminal-like
TP53 status Wildtype Mutated Mutated Mutated
Volume doubling time NA 1-2 days NA 7 days
Proliferation index (Ki67) Missing 28% Missing 35%
Summary of characteristics related to genotype and phenotype of the xenograft models
* Measured at the DNA level by array Comparative Genomic Hybridization (aCGH)
** The primary basal-like carcinoma had very weak cytoplasmic staining for PgR29.
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assignments were performed based on a previous HR
MAS MRS study of breast cancer lesions [30]. One HR
MAS MRS spectrum from the MAS98.06 animals was
lost due to technical error.
The regions from 0.20 to -0.20 ppm (TSP), -0.85 to
-1.15 ppm (ERETIC) and 3.60 to 2.90 ppm (glycine,
taurine, GPC, PCho, choline, and creatine) were selected
for quantification in all spectra. Peak areas were calcu-
lated by curve fitting (PeakFit v 4, Systat Software Inc)
using a combination of Gaussian and Lorentzian line-
shapes (Voigt function). The correlation coefficient of
the fit (r2) was > 0.95 for all spectra. The ERETIC signal
was quantified to 3.17 × 10-7 moles using a series of
creatine calibration standards as previously described
[31]. Concentrations of tissue metabolites ([MET]) were
calculated relative to the ERETIC signal using equation
(1):
[ ]MET
A
A k
n
m
MET
ERETIC MET
ERETIC
sample
= × ×
1
(1)
AMET and AERETIC are the calculated areas of the
metabolite and the ERETIC signals, respectively; kMET is
the number of protons giving rise to the metabolite sig-
nal; nERETIC is the number of moles the ERETIC signal
represents; and msample is the mass of the sample. The
metabolite concentrations measured using the ERETIC
signal were compared using a 2-sided Student’s t-test
with a significance level of p < 0.05 using Sigmaplot
11.0 (Systat Software Inc.).
HR MAS MRS of human tissue samples
Human tissue samples were prepared for HR MAS MRS
analysis using the same procedure as the xenograft sam-
ples. Spectra were acquired using a spin-echo Carr-Pur-
cell-Meiboom-Gill sequence (cpmgpr; Bruker) with 2 s
water suppression prior to a 90° excitation pulse. The
spin-echo sequence for suppression of broad peaks was
performed using a delay of 1 ms repeated 136 times,
resulting in an effective echo time of 285 ms. A total of
128 scans over a spectral region of 10 kHz were col-
lected into 32k points during 1.64 s. The spectra were
Fourier transformed into 128 K after 0.3 Hz exponential
line broadening, and the metabolite region from 3.60 to
3.00 ppm was selected for further evaluation. The spec-
tra were normalized by scaling the spectral data of all
samples to achieve an equal total area for each spec-
trum. Metabolite peak areas were then obtained by
curve fitting as described above.
Histopathology
Following HR MAS MRS analysis, the xenograft samples
were fixed in 10% neutral buffered formalin and
embedded in paraffin. One histopathological section
were prepared from each sample, stained with hematox-
ylin/eosin/saffron (HES) according to standard protocol
and evaluated microscopically. A visual evaluation with
respect to the presence of viable tumor tissue and the
extent of necrosis was performed. Tumor grade, hor-
mone receptor status and HER2 expression of human
tissue samples was obtained from hospital records. In
addition, specimens analysed by HR MAS MRS were
HES-stained and the relative areas of normal and neo-
plastic epithelial tissue, necrotic tissue, fat and fibrous
connective tissue were scored.
Gene expression analysis
Gene expression analysis was performed on tumor tis-
sue from 6 animals from each of the two xenograft
models, using a one-color microarray-based platform
(Agilent). Total RNA was isolated from snap frozen
tumor tissue using TRIzol (Invitrogen) and resus-
pended in RNase-free water. Total RNA (700 ng) was
amplified, labelled with Cy3, and 1.65 μg cRNA was
hybridized to 4 × 44 k Agilent Whole Human Genome
Oligo Microarrays at 60°C and 10 rpm for 17 hours,
according to the manufacturer’s protocol. The arrays
were scanned using an Agilent G2565A DNA microar-
ray scanner and extracted using Feature Extraction (v
10.1.1.1, Agilent). One microarray from the MAS98.06
model was removed due to poor array quality. The
microarray data was normalized and analysed using R
(v 2.9.0) and the LIMMA Bioconductor package [32].
The raw signals were corrected for multiplicative
detrending effects and the arrays were quantile nor-
malized and log2 transformed. Probes which were
flagged as outliers by the Feature Extraction software
or were present in less than 30% of the samples, were
removed. The signal intensities were averaged between
duplicate probes, and the probe with the highest inter-
quartile range was selected to represent each unique
transcript.
Table 2 Summary of patient characteristics
Subtype n Patient age
(years)
Phenotype Tumor
grade1/2/3
Tumor size
(cm)
Mean tumor
fraction (%)
Mean connective tissue
fraction (%)
Mean fatty tissue
fraction (%)
ER+/PgR+ 14 57 ± 16 ER+/PgR+ 1/10/3 2.3 ± 1.3 23 ± 11 72 ± 11 5 ± 7
Triple
negative
8 57 ± 17 ER-/PgR-/
HER2-
0/3/5 2.2 ± 1.0 38 ± 32 55 ± 31 6 ± 7
Summary of patient and sample characteristics of the different subgroups of human tissue samples (mean ± SD)
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A total of 119 genes were selected for further analysis.
The selection criteria were a) genes involved in KEGG
homo sapiens glycerophospholipid pathway hsa:00564
[33], or b) genes coding for proteins reported to be
directly involved in choline transport and choline and
glycine metabolism [16,34-36]. Of the selected genes,
117 were represented on the microarray (full gene list
supplied as additional file 1).
Testing for differential expression between the xeno-
graft models was performed using t-tests with Empirical
Bayesian correction of the test statistics [32]. To account
for multiple testing, an adjusted p-value of 0.05 (using
Benjamini & Hochberg’s false discovery rate) was
defined as the threshold for significant differential
expression between the xenograft models. The microar-
ray data from the significantly differentially expressed
genes was centered across genes and clustered across
genes and samples using hierarchical clustering with
Euclidian distance and complete linkage. The relation-
ship between gene expression and metabolite concentra-
tions was explored using Ingenuity Pathways Analysis
(Ingenuity Systems), and an illustration was adapted
from the canonical Glycerophospholipid Metabolism
and Glycine, Serine and Threonine Metabolism path-
ways [33]. The abovementioned gene list was also
extracted from microarray data from previously
described passages of the same xenograft models [29],
to ensure that gene expression remain stable throughout
serial transplantation of the xenografts.
Results
Histopathology
All xenograft samples were found to contain mainly
viable tumor tissue and stromal connective tissue,
shown previously to be recruited mouse stromal tissue
[29], with negligible necrosis (< 10% area) in 18 of 19
samples. The HR MAS MRS data was therefore consid-
ered to be representative of the metabolite concentra-
tions in the solid tumors. One sample in the MAS98.06
group contained a necrotic area, microscopically esti-
mated to 25% area of the specimen. However, the meta-
bolite concentrations measured in this sample differed
from the group mean by less than ± 2 SD, and the sam-
ple was therefore not excluded from the data set. The
mean fractions of tumor and connective tissue in the
human tissue samples are presented in Table 2.
HR MAS MRS of xenograft samples
The HR MAS MRS analyses revealed several significant
differences in the metabolic profiles of the two xenograft
models. Mean 1H HR MAS MRS spectra from the two
models are shown in Figure 1 (spectral region 3.6 - 3.0
ppm). The metabolites assigned in Figure 1 were quanti-
fiable in all spectra. The metabolite concentrations
calculated using the ERETIC reference signal are pre-
sented in Table 3. There was no significant difference in
choline concentration between the models. However,
the concentrations of GPC and PCho were significantly
higher than the choline concentration in both the basal-
like and the luminal-like model. While all the samples
from basal-like xenografts showed higher concentration
of GPC than PCho, the samples from luminal-like xeno-
grafts invariably showed lower concentrations of GPC
than PCho. The differences in GPC and PCho concen-
trations between the two xenograft models were statisti-
cally significant (p < 0.001 and p < 0.01, respectively).
The concentration of glycine was significantly higher in
the basal-like than in the luminal-like model (p < 0.002).
HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples
were retrieved from our internal database, and mean
spectra from the two groups are shown in Figure 1. The
mean metabolite profiles demonstrated that triple nega-
tive breast cancer tissue had high GPC and low PCho
concentrations, whereas tissue from ER+/PgR+ patients
had low GPC and high PCho. There was a significant
difference in the GPC/PCho peak area ratio between ER
+/PgR+ and triple negative samples (0.8 ± 0.5 and 1.5 ±
0.7, respectively. p = 0.01), corresponding to the findings
from the xenograft models. The mean spectra from
human tissue samples also suggested that the glycine
concentration was higher in triple negative breast cancer
tissue samples. Using the glycine/total peak area ratio as
marker for glycine content, this trend was not statisti-
cally significant (p = 0.19). The relative choline peak
area was significantly higher in triple negative tissue
(p < 0.00003) and the relative creatine peak area was
significantly lower (p = 0.024).
Gene expression analysis of xenograft tissue
Of the 119 investigated genes, 67 were differentially
expressed between the xenograft models at a 5% adjusted
(false discovery rate) significance level. Microarray data
from earlier passages of the same xenograft models [29]
showed similar trends of differential expression (data not
shown). The complete results from the gene expression
analysis are available as additional file. A heatmap of the
differentially expressed genes is presented in Figure 2, with
hierarchical clustering of genes and samples. In the follow-
ing sections, only genes directly involved in synthesis and
degradation of PtdCho from choline are considered.
Among the five selected genes coding for proteins
known to be involved in transmembrane choline trans-
port, only solute carrier family 44, member 1 (SLC44A1)
showed significantly different expression between the
two models. The expression of this transporter, also
known as choline transporter-like protein 1 (CTL1), was
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lower in basal-like than luminal-like xenografts. Solute
carrier family 22, member 1 (SLC22A1) and solute car-
rier family 44, member 2 (SLC44A2) were similarly
expressed in the two models, whereas solute carrier
family 5 (choline transporter), member 7 (SLC5A7) and
solute carrier family 22 (organic cation transporter),
member 2 (SLC22A2), were expressed below the limit of
detection. SLC5A7 is also known as choline transporter
1 (CHT1), a high-affinity choline-specific transporter
protein, whereas SLC44A2 is also known as choline-
transporter like protein 2 (CTL2).
Genes directly involved in choline metabolism which
were differentially expressed between the xenograft
models are listed in Table 4 and 5. A schematic
overview of intracellular choline metabolite concentra-
tions and the comparative gene expression (the anabolic
Kennedy pathway, PtdCho breakdown and conversion of
choline to glycine) between the xenograft models is pre-
sented in Figure 3. As shown in Figure 3, choline is con-
verted to PCho through the action of two isoforms of
the same enzyme, choline kinase alpha and beta. The
expression of the genes (CHKA, CHKB) coding for both
isoforms was significantly lower in the basal-like than in
the luminal-like model.
Conversion of PCho to CDP-choline is mediated
through the alpha and beta isoforms of phosphate cyti-
dylyl transferase 1 (PCYT1A and PCYT1B). The expres-
sion of PCYT1B was significantly higher, and PCYT1A
was significantly lower in the basal-like than the lumi-
nal-like model. The gene coding for choline phospho-
transferase 1 (CHPT1), which converts CDP-PCho to
PtdCho, had a significantly lower expression level in the
basal-like than in the luminal-like model.
PtdCho is degraded by several different phospholi-
pases. Enzymes in the phosphoplipase A2 group (PLA2)
convert PtdCho to acyl-GPC. Of the 13 PLA2 isoforms
studied, two were significantly higher expressed in the
basal-like model, three were significantly lower
expressed, five showed no significant difference in
expression and three were below the limit of detection.
Figure 1 Mean HR MAS MRS spectra from human tissue samples and xenograft tissue. HR MAS MRS spectra (spectral region 3.6 to 3.0
ppm) of ER+/PgR+ (top left) and triple negative (top right) human tissue samples, and luminal-like (bottom left) and basal-like (bottom right)
xenograft samples. Spectral assignments are provided for peaks used in quantification.
Table 3 Metabolite concentrations
MAS98.12 (n = 10) MAS98.06 (n = 9)
Creatine 4.1 ± 1.4 3.4 ± 1.7
Choline 1.2 ± 0.7 0.9 ± 0.6
Phosphocholine * 4.5 ± 2.1 9.1 ± 4.4
Glycerophosphocholine ** 9.8 ± 2.5 2.7 ± 1.7
Taurine 14.7 ± 4.1 19.1 ± 9.1
Glycine * 8.2 ± 3.0 4.0 ± 1.8
Metabolite concentrations in basal-like (MAS98.12) and luminal-like
(MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC
method (μmol/g, mean ± SD, * p < 0.01, ** p < 0.001)
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The largest difference in gene expression between the
two models was found for PLA2G4A, where a log2-fold
difference of 6.4 in gene expression was observed. Phos-
pholipase B1 (PLB1) is involved in both deacetylation
steps from PtdCho to GPC, and was significantly higher
expressed in the basal-like than in the luminal-like
model.
Phospholipase D, with the two isoforms PLD1 and
PLD2, converts PtdCho to choline. The expression of
PLD1 was significantly higher and the expression of
PLD2 was significantly lower in the basal-like compared
to the luminal-like model. Other genes related to the
degradation of PtdCho, such as lecithin-cholesterol acet-
yltransferase (LCAT) and phosphatidylserine synthase 1
(PTDSS1) also had significantly higher expression levels
in the basal-like than in the luminal-like model. The
GDPD5 gene, coding for glycerophosphodiester phos-
phodiesterase (GDPD) was significantly higher expressed
in the basal-like model than in the luminal-like model,
indicating that GPC degradation may occur at a higher
rate in basal-like xenografts. However, an isoform of this
gene, GDPD1, was higher expressed in the luminal-like
xenografts. As shown in Figure 3, choline dehydrogenase
(CHDH) mediates the irreversible conversion of choline
to betaine, which is a key precursor in the synthesis of
glycine. The expression of CHDH was significantly
higher in the basal-like than in the luminal-like model.
Sarcosine dehydrogenase (SARDH), involved in the con-
version of betaine to glycine, also had significantly
higher expression levels in the basal-like model.
Discussion
The HR MAS MRS data demonstrated significant differ-
ences in choline metabolite pattern between the basal-
like and luminal-like xenograft models. In particular, the
difference in GPC and PCho concentrations is an inter-
esting finding, as the pattern seen in the basal-like
model does not correspond to typical in vitro choline
metabolite patterns [15,17]. In addition, expression data
showed that several genes directly associated with cho-
line metabolism differed significantly between the two
models. Differences in expression of genes involved in
choline metabolism corresponded to differences in
metabolite concentrations, suggesting that transcrip-
tional differences between the models are reflected in
the HR MAS MRS spectra. The relative amounts of
GPC and PCho in human tissue samples from triple
negative and ER+/PgR+ subtypes of breast cancer corre-
sponded well with the data from the xenografts.
In order to evaluate if the choline metabolism in the
xenograft models is representative for basal-like and
luminal-like breast cancer in humans, they were com-
pared to data from triple negative and ER+/PgR+ breast
cancer patients. It is assumed that the triple-negative
Figure 2 Heatmap of differentially expressed genes in
xenograft models. Hierarchical clustering of the 67 differentially
expressed genes (false discovery rate < 0.05) involved in the KEGG
homo sapiens glycerophospholipid pathway hsa:00564, choline
transport or directly involved in conversion from choline to glycine
(Red: high expression compared to mean expression in xenograft
samples. Blue: low expression compared to mean expression in
xenograft samples). The microarray data was centred across genes
and clustered across genes and samples using Euclidian distance
and complete linkage.
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phenotype is a valid surrogate marker for basal-like
breast cancer, as approximately 90% of triple-negative
breast carcinomas can be classified as basal-like based
on the intrinsic molecular subtyping developed by Sørlie
et al [3,37]. On the other hand, expression of estrogen
and/or progesterone receptors is a typical feature of
luminal A and B subtypes, whereas the ERBB2 and
basal-like subtypes of breast cancer rarely express hor-
mone receptors [38,39]. Therefore, the ER+/PgR+ phe-
notype is considered to be a valid surrogate marker for
luminal-like subtypes of breast cancer.
Using gene expression profiling, the molecular causes
for the differences in choline metabolism was further
explored in the xenograft models. The heatmap of all 64
significantly differentially expressed genes in Figure 2,
clearly shows that different sets of genes related to
phospholipid metabolism are higher expressed the basal-
like model compared to the luminal-like models. This
indicates that the regulation of choline metabolism differ
between the two xenograft models. Although this study
does not provide data on metabolic flux, the methods
used are suitable for highlighting key steps in choline
metabolism. Comparison of these two disease models
does not, however, give any information with respect to
the difference between choline metabolism in normal
breast versus breast cancer tissue. Nevertheless, gene
expression profiling of the xenograft models showed sig-
nificant differences in the expression of genes directly
involved in choline metabolism, suggesting that these
genes may play key roles in regulation of choline meta-
bolite concentrations in human breast cancer.
Increased choline transport has been associated with
the abnormally high concentrations of PCho observed in
breast cancer [16,27,40]. In our study, the influx of cho-
line in the two models could not be fully evaluated from
the gene expression data, as only one of five investigated
Table 4 Differentially expressed genes
Entrez
ID
Probe name Gene
name
Encoded protein Log2-fold
difference
Adjusted p-value (false
discovery rate)
5321 A_23_P11685 PLA2G4A Phospholipase A2, group IV A 6.4 4.4E-16
55349 A_23_P69293 CHDH Choline dehydrogenase 3.3 4.0E-13
1757 A_24_P35400 SARDH Sarcosine dehydrogenase 2.5 7.6E-12
9468 A_24_P941353 PCYT1B Phosphate cytidylyltransferase 1, choline, beta 1.7 3.7E-9
31896 A_23_P87401 GDPD5 Glycerophosphodiester phosphodiesterase domain
containing 5
1.0 4.2E-6
8681 A_23_P403424 PLA2G4B Phospholipase A2, group IV B 0.9 9.8E-5
9791 A_23_P168868 PTDSS1 Phosphatidylserine synthase I 0.9 9.6E-7
10434 A_23_P19192 LYPLA1 Lysophospholipase 1 0.9 0.001
3931 A_23_P218237 LCAT Lecithin-cholesterol acyltransferase 0.8 0.0002
151056 A_23_P56356 PLB1 Phospholipase B1 0.7 0.0001
5337 A_23_P155335 PLD1 Phospholipase D1 0.7 0.0005
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors
Table 5 Differentially expressed genes
Entrez
ID
Probe name Gene
name
Encoded protein Log2-fold
difference
Adjusted p-value (false
discovery rate)
50487 A_23_P17814 PLA2G3 Phospholipase A2, group III -3.1 1.1E-12
81579 A_23_P30020 PLA2G12A Phospholipase A2, group XII A -1.6 2.5E-9
56994 A_23_P105571 CHPT1 Choline phosphotransferase 1 -1.4 1.6E-7
23446 A_23_P216630 SLC44A1 Solute carrier family 44, member 1 (CTL1) -1.1 7.9E-7
5338 A_23_P4308 PLD2 Phospholipase D2 -1.1 1.2E-6
8399 A_23_P88767 PLA2G10 Phospholipase A2, group X -1.1 3.1E-6
1119 A_23_P314120 CHKB Choline kinase beta -0.8 2.0E-6
11313 A_24_P276490 LYPLA2 Lysophospholipase II -0.4 0.005
5130 A_23_P252681 PCYT1A Phosphate cytidylyltransferase 1, choline, alpha -0.4 0.035
24657 A_23_P84666 GDPD1 Glycerophosphodiester phosphodiesterase domain
containing I
-0.4 0.005
1119 A_23_P124742 CHKA Choline kinase, alpha -0.3 0.047
Genes directly involved in choline metabolism with significantly lower expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors
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choline transporters was differentially expressed. Choline
transport has been shown to be less important than
PtdCho turnover for total choline metabolite concentra-
tions [17]. Differences in choline uptake may still have
impact on the choline metabolite concentrations, and
specific studies using isotopically labelled choline could
possibly allow accurate evaluation of choline transport
rate in the two xenograft models.
In breast cancer cells, the intracellular metabolism of
choline is divided in two major pathways as shown in
Figure 3: Betaine production or PtdCho synthesis
[27,34]. In the betaine synthesis pathway, choline is oxi-
dized to betaine through the action of choline dehydro-
genase (CHDH). Betaine is then demethylated to glycine.
In vitro studies of MCF7-cells have shown that PtdCho
synthesis is the pathway predominantly accountable for
choline turnover [34]. The first step in the PtdCho
synthesis pathway is the phosphorylation of choline
through choline kinase, yielding PCho (Figure 3). It has
been shown that increased expression of CHKA is
Figure 3 Differences in gene expression and metabolite concentrations. Differences in intracellular choline metabolism, choline transport
and glycine formation between basal-like and luminal-like xenografts. Red: higher gene expression/metabolite concentration in basal-like
xenografts. Blue: higher gene expression/metabolite concentration in luminal-like xenografts. White: Non-significant difference in expression/
concentration. Log2-fold difference between models is indicated by color intensity. Only significantly differentially expressed genes are illustrated
at each EC number, which represents specific enzymatic reactions. The metabolites which were measured with HR MAS MRS are outlined with a
thicker line.
Moestue et al. BMC Cancer 2010, 10:433
http://www.biomedcentral.com/1471-2407/10/433
Page 9 of 12
critical for proliferation both of mammary epithelial
cells and breast cancer [41], but in vitro studies of dif-
ferent breast cancer cell lines have not conclusively
demonstrated a correlation between CHKA expression
and PCho concentration [16,26]. In our study, the
expression of CHKA and CHKB was significantly lower
in the basal-like than in the luminal-like model,
although some variability in expression was observed
(Figure 2). This is consistent with the lower PCho con-
centrations measured in the basal-like model. Betaine
production is thought to contribute only slightly to the
overall conversion of choline, and neither choline trans-
port nor GPC degradation is conclusive with respect to
their contribution to the choline pool. As normal breast
tissue or benign breast lesions rarely exhibit increased
choline metabolite levels, the xenograft models are
believed to represent typical choline metabolism
abnormalities of breast carcinomas [42,43]. Therefore, it
should be stressed that CHKA and CHKB expression is
likely to be upregulated in both xenograft models com-
pared to normal breast tissue. The lower PCho concen-
trations in the basal-like xenografts may also in part be
a result of higher CHDH expression. This suggests that
conversion of choline to betaine is upregulated, shifting
the metabolic flux in favour of glycine formation.
SARDH, related to conversion of betaine to glycine, was
also significantly higher expressed in the basal-like
model. The concentration of glycine in the basal-like
model was indeed higher than in the luminal-like
model, suggesting that there is a difference in choline
routing and glycine production between the two breast
cancer subtypes. An association between tumor aggres-
siveness and glycine concentration has been noted also
in clinical breast cancer tissue biopsies [21]. Abnormal-
ities in cancer energy metabolism are widely recognized,
and differences in glycine concentration between the
two xenograft models in this study could well be an
indirect result of this phenomenon.
Degradation of PtdCho is the primary source of GPC.
The expression of PLA2G4A, PLA2G4B, LCAT, LYPLA1
and PLB1, which all are associated with this pathway, was
higher in the basal-like model. Other genes (PLA2G3,
PLA2G12A, PLA2G10, LYPLA2) were lower expressed in
the basal-like model, and a clear association between
PtdCho degradation and GPC concentration could not
be concluded. However, in vitro studies have suggested
that GPC concentrations are associated with PLA2G4A
levels, which is consistent with our findings [17]. A lower
rate of GPC degradation could account for the higher
GPC concentration observed in the basal-like xenograft
model. The expression of GDPD5 was, however, higher
in basal-like xenografts. The observed differences
between the two models in the relative expression of dif-
ferent genes assigned to the abovementioned enzymatic
steps could be reflecting the relative importance of differ-
ent gene products coding for proteins with the same
enzymatic activity in the two models.
By associating choline metabolite concentrations with
tumor cell phenotype, it has been proposed that PCho con-
centration increase with the malignancy of the tumor cell
line when grown in culture [15]. However, other in vitro
studies have failed to show a correlation between malig-
nancy and choline metabolite concentrations [16]. It has
been suggested that differences in experimental design,
particularly the stage of cell growth, are accountable for
these discrepancies [26]. In all the abovementioned in vitro
studies of breast cancer cells, PCho concentrations were
significantly higher than GPC concentrations. However,
both in xenograft models of breast cancer and in clinical
tissue samples, GPC concentrations higher than PCho con-
centrations have been observed [21,44]. GPC concentration
has been shown to be negatively correlated with estrogen
receptor content in breast carcinomas, which agrees with
the relatively high GPC content in the basal-like xenograft
[45]. Our data show that GPC concentration is significantly
lower and PCho concentration is significantly higher in the
luminal-like animal model, which represents a less aggres-
sive disease than the basal-like model. This suggests that
the relationship between choline metabolite concentrations
and malignancy of solid tumors is more complex than indi-
cated by studies of breast cancer cell lines. Discrepancies
between in vitro data and clinical data may be attributed to
the microenvironment of solid tumors. It has recently been
shown that the metabolic profiles change when the same
breast cancer cell lines are studied both in vitro and in vivo
[46]. In addition, in vitro simulation of microenvironmental
factors in solid tumors has demonstrated that PCho and
GPC concentrations respond to changes in acidity, oxyge-
nation level and glucose accessibility [44].
The relevance of the basal-like and luminal-like xeno-
grafts used in this study was further supported by com-
paring the choline metabolite pattern with that of
human tissue samples from ER+/PgR+ and triple nega-
tive breast cancer. Evaluation of metabolite levels
through relative peak areas demonstrated that the mean
GPC/PCho ratio was significantly higher in triple nega-
tive breast cancer than in ER+/PgR+ breast cancer. The
relative PCho area was significantly higher in ER+/PgR+
samples than in samples from triple negative breast can-
cer. A trend towards higher glycine concentration was
also found in triple negative tissue samples. Interest-
ingly, the choline concentration in triple negative breast
cancer was higher than in ER+/PgR+ breast cancer.
Overall, the striking similarity between xenografts and
human tissue samples with respect to GPC and PCho
levels suggest that the xenografts have maintained
genetic and/or microenvironmental features from the
primary carcinomas which are relevant for the choline
Moestue et al. BMC Cancer 2010, 10:433
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metabolite pattern. The spectra from human tissue sam-
ples also suggest that PCho concentrations alone are not
a reliable prognostic biomarker. The triple negative sam-
ples represent disease with poor prognosis, yet the PCho
level in these samples appear to be significantly lower
than in ER+/PgR+ samples. This finding encourages
large-scale studies of the metabolite pattern and gene
expression in the different molecular subtypes of breast
cancer, as this may reveal new drug targets or suggest
strategies for individualised therapy using drugs target-
ing the choline metabolism pathways.
When interpreting the gene expression data from the
two xenograft models, it should be kept in mind that
gene expression not always represents the actual enzy-
matic activity. Isoforms of the same enzyme may exhibit
differences in transcriptional regulation, and mRNA
concentrations do not account for post-translational
modification of enzymes. In addition, the concentrations
of all investigated choline-containing compounds are
determined by more than one metabolic reaction. Thus,
a simplistic model for correlating gene expression with
metabolite concentration is not applicable. The net rate
of all relevant metabolic reactions governs the metabo-
lite concentrations, and the relative importance of each
metabolic reaction is unknown. This must be kept in
mind when interpreting the data. However, the gene
expression data provide significant information in terms
of highlighting the reactions that are most likely to be
relevant for the observed differences in metabolic pat-
tern. Hypotheses generated on the basis of microarray
data should be evaluated by tracking the flux of metabo-
lites through the different pathways.
Comparing our data with pre-existing studies of cho-
line metabolism in cultured cells and in vivo models with
data from human biopsies, we suggest that primary
tumor xenografts are more relevant model systems than
cell cultures with respect to investigation of metabolic
profiles in different breast cancer subtypes, and may be a
better approach to studies of therapeutic efficacy in the
different breast cancer subtypes. As the choline metabo-
lite profile of the xenograft models used in the study
appear representative of basal-like and luminal-like
human breast cancer, the models are considered valuable
tools for testing of targeted drugs and for monitoring
response to treatment in these subtypes of breast cancer.
Conclusions
HR MAS MRS analyses of a basal-like and a luminal-like
xenograft model demonstrated significant differences in
choline metabolite concentrations. In the more aggressive
basal-like tumor, GPC concentrations were higher than
PCho concentrations, whereas this pattern was reversed in
the luminal-like model. Glycine concentration was also
significantly higher in the basal-like model. These
differences could at least in part be explained by lower
choline kinase expression and increased PtdCho degrada-
tion in the basal-like model. The gene expression data also
suggested a possible shift in metabolic flux from PtdCho
synthesis to glycine formation in the basal-like model. The
choline metabolism pattern in the xenografts corre-
sponded well with spectra from tissue samples from triple
negative and ER+/PgR+ human breast carcinomas, sug-
gesting that the basal-like and luminal-like xenografts may
be a relevant model system for studies of choline metabo-
lism in these two subtypes of human breast cancer.
Additional material
Additional file 1: Differential gene expression. Excel spreadsheet
containing results from the differential gene expression analysis of the
119 investigated genes.
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